Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients

July 22, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search